43.13
price up icon1.29%   0.55
after-market After Hours: 42.20 -0.93 -2.16%
loading
Legend Biotech Corp Adr stock is traded at $43.13, with a volume of 1.32M. It is up +1.29% in the last 24 hours and down -3.60% over the past month. Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$42.58
Open:
$42.96
24h Volume:
1.32M
Relative Volume:
1.06
Market Cap:
$7.82B
Revenue:
$455.99M
Net Income/Loss:
$-285.01M
P/E Ratio:
-13.23
EPS:
-3.26
Net Cash Flow:
$-164.61M
1W Performance:
+7.45%
1M Performance:
-3.60%
6M Performance:
+4.15%
1Y Performance:
-29.94%
1-Day Range:
Value
$41.73
$43.56
1-Week Range:
Value
$38.68
$43.56
52-Week Range:
Value
$36.92
$70.13

Legend Biotech Corp Adr Stock (LEGN) Company Profile

Name
Name
Legend Biotech Corp Adr
Name
Phone
-
Name
Address
-
Name
Employee
1,800
Name
Twitter
@LegendBiotech
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
LEGN's Discussions on Twitter

Compare LEGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LEGN
Legend Biotech Corp Adr
43.13 7.82B 455.99M -285.01M -164.61M -3.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
464.56 119.70B 10.63B -479.80M -1.35B 13.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
754.87 82.75B 13.85B 4.65B 3.32B 35.06
Biotechnology icon
ARGX
Argen X Se Adr
614.59 36.73B 1.86B -40.29M -1.28B -4.16
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.74 32.53B 2.09B -332.26M 16.06M -4.14
Biotechnology icon
BNTX
Biontech Se Adr
120.72 28.50B 3.30B -501.07M 1.03B 11.54

Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-08-24 Initiated Redburn Atlantic Buy
Jun-17-24 Initiated Truist Buy
May-24-24 Reiterated H.C. Wainwright Buy
May-23-24 Initiated Deutsche Bank Buy
Apr-17-24 Upgrade Scotiabank Sector Perform → Sector Outperform
Apr-03-24 Initiated Cantor Fitzgerald Overweight
Mar-13-24 Initiated Raymond James Outperform
Dec-19-23 Initiated Scotiabank Sector Perform
Nov-06-23 Initiated Goldman Buy
May-25-23 Initiated William Blair Mkt Perform
May-22-23 Initiated Daiwa Securities Buy
Mar-29-23 Initiated H.C. Wainwright Buy
Mar-24-23 Initiated RBC Capital Mkts Outperform
Dec-06-22 Initiated UBS Buy
Nov-02-22 Initiated Evercore ISI Outperform
Nov-01-22 Initiated Cowen Outperform
Oct-31-22 Initiated Guggenheim Neutral
Jun-17-22 Initiated BMO Capital Markets Outperform
Mar-15-22 Initiated Barclays Overweight
Jan-31-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-21-21 Initiated Piper Sandler Overweight
May-18-21 Initiated BTIG Research Buy
Jul-01-20 Initiated JP Morgan Overweight
Jul-01-20 Initiated Jefferies Buy
Jun-30-20 Initiated Morgan Stanley Overweight
View All

Legend Biotech Corp Adr Stock (LEGN) Latest News

pulisher
Nov 24, 2024

Earnings call: Legend Biotech sees strong growth with CARVICTI sales - Investing.com India

Nov 24, 2024
pulisher
Nov 22, 2024

Legend Biotech Corp ADR (NASDAQ: LEGN) Has Great Upside Potential - Stocks Register

Nov 22, 2024
pulisher
Nov 22, 2024

Thinking Of Investing In Bilibili Inc ADR (NASDAQ: BILI) Stock? Read This First - Stocks Register

Nov 22, 2024
pulisher
Nov 22, 2024

Are Medtronic Plc (NYSE: MDT) Analysts Predicting A Spike? - Stocks Register

Nov 22, 2024
pulisher
Nov 21, 2024

Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Nov 21, 2024
pulisher
Nov 19, 2024

Parkway Corporate Limited Announces New Securities Issuance - MSN

Nov 19, 2024
pulisher
Nov 15, 2024

Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com

Nov 15, 2024
pulisher
Nov 14, 2024

Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa

Nov 14, 2024
pulisher
Nov 12, 2024

Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Nov 12, 2024
pulisher
Nov 06, 2024

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.

Nov 06, 2024
pulisher
Nov 05, 2024

Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com

Nov 05, 2024
pulisher
Nov 04, 2024

Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Legend Biotech appoints new President for CARVYKTI - Investing.com

Nov 04, 2024
pulisher
Oct 28, 2024

Legend Biotech Corp ADR (NASDAQ:LEGN) Stock Is up 15.91% From Its Low, This Stock Is Just Warming Up - Stocks Register

Oct 28, 2024
pulisher
Oct 24, 2024

Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade - Yahoo Finance

Oct 24, 2024
pulisher
Oct 17, 2024

Adma Biologics Inc (ADMA) Should Be Considered For The Next Few Weeks - Stocks Register

Oct 17, 2024
pulisher
Oct 17, 2024

Legend Biotech shares hold Buy rating, $91 target despite Q3 CARVYKTI sales - Investing.com India

Oct 17, 2024
pulisher
Oct 17, 2024

Legend Biotech shares hold as Barclays maintains $94 target - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Company’s Banking Stock: Dissecting a -18.35% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Oct 16, 2024
pulisher
Oct 16, 2024

Redburn Atlantic initates Legend Biotech Corp ADR (LEGN) rating to a Buy - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Li Auto Inc ADR (LI) rating downgrades by Macquarie - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Recent Insider Activity Suggests Potential Gains for Enovix Corporation (ENVX) - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

BMO maintains steady target on Legend Biotech on strong sales - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

BMO maintains steady target on Legend Biotech on strong sales By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 15, 2024

Stock Performance Spotlight: Legend Biotech Corp ADR (LEGN) Ends the Day at 49.68, Down by -0.64 - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

Legend Biotech Corp ADR’s results are impressive - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

UnitedHealth, NVIDIA lead Tuesday's afternoon market cap stock movers By Investing.com - Investing.com UK

Oct 15, 2024
pulisher
Oct 11, 2024

Legend Biotech maintains shares price target on steady Q3 growth - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Legend Biotech Corp ADR’s Mixed Bag: Down -8.63% in 6 Months, Down 1.03% in 30 Days - The InvestChronicle

Oct 11, 2024
pulisher
Oct 10, 2024

Market Insights: Legend Biotech Corp ADR (LEGN)’s Notable Gain of 1.62, Closing at 48.84 - The Dwinnex

Oct 10, 2024
pulisher
Oct 09, 2024

Legend Biotech shares hold strong with positive outlook on robust Carvykti sales - Investing.com

Oct 09, 2024
pulisher
Oct 08, 2024

Legend Biotech Corp ADR (LEGN) is a good investment, but the stock may be overvalued - US Post News

Oct 08, 2024
pulisher
Oct 08, 2024

Redburn sees growth potential for Legend Biotech stock on Carvykti demand - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

Does Legend Biotech Corp ADR (LEGN) offer a good opportunity for investors? - SETE News

Oct 07, 2024
pulisher
Oct 04, 2024

Legend Biotech stock maintains positive outlook with new Philadelphia R&D facility - Investing.com

Oct 04, 2024
pulisher
Oct 03, 2024

Upward Trajectory: Legend Biotech Corp ADR (LEGN) Posts a Gaine, Closing at 48.68 - The Dwinnex

Oct 03, 2024
pulisher
Oct 02, 2024

Legend Biotech Corp ADR (LEGN) stock analysis: A simple moving average approach - US Post News

Oct 02, 2024
pulisher
Oct 01, 2024

You might want to take a look at Legend Biotech Corp ADR (LEGN) now - SETE News

Oct 01, 2024
pulisher
Sep 30, 2024

Legend Biotech shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

BMO maintains Outperform rating on Legend Biotech shares on Carvykti data - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Legend Biotech shares maintain Buy rating from H.C. Wainwright - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Legend Biotech's SWOT analysis: carvykti success drives stock potential - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Legend Biotech reiterates stock target, overweight on Phase III data - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Legend Biotech stock poised for growth with compelling data on Carvykti - Investing.com

Sep 30, 2024
pulisher
Sep 26, 2024

Legend Biotech Corp ADR (LEGN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Sep 26, 2024
pulisher
Sep 25, 2024

Can you now get a good deal on Legend Biotech Corp ADR’s shares? - US Post News

Sep 25, 2024

Legend Biotech Corp Adr Stock (LEGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price down icon 1.35%
$75.45
price up icon 0.87%
$43.39
price up icon 3.19%
$378.13
price up icon 0.30%
$206.16
price up icon 7.31%
$120.72
price up icon 1.84%
Cap:     |  Volume (24h):